Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This phase 4 study will explore, in the context of the present French clinical practice, the
impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for
etiologic determination of the cognitive and functional impairment, but in whom:
1. lumbar puncture was not feasible for medical conditions
2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating
physicians
3. lumbar puncture (LP) was refused by the patient